| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Profit before tax | -2.5 | -1.9 |
| Net income | -2.5 | -1.9 |
| EPS (diluted, $ a share) | $-0.57 | $-10.81 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: ENVB. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Enveric Biosciences, Inc.: key numbers
- Share price
- $1.44Close, Nov 16
- Market cap
- $6.45M
- Shares outstanding
- 4.48MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Enveric Biosciences, Inc.
All →Enveric Biosciences Financial Results
Enveric Biosciences reported financial results for the third quarter of 2026 and provided a corporate update on its lead candidate EB-003. The company is completing final IND-enabling activities for EB-003, a non-hallucinogenic neuroplastogenic candidate, with plans for an IND submission and Phase 1 clinical trial.
- Term
- Q3 2026
“Our focus during the third quarter was advancing final IND-enabling activities for EB-003 as we prepare for the planned IND submission and first-in-human Phase 1 clinical trial of our lead non-hallucinogenic, neuroplastogenic candidate.”
Joseph Tucker, Ph.D., Chief Executive Officer of Enveric
“The growing body of preclinical evidence reinforces our confidence in this opportunity as we complete the final IND-enabling activities and prepare to advance EB-003 toward first-in-human clinical development.”
Joseph Tucker, Ph.D., Chief Executive Officer of Enveric